Oncology/Hematology
Hematology
More in Hematology
In phase III study, recombinant VWF not superior to cheaper alternative for type 1 and 2 cases
Jun 29, 2023
Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate
Jun 16, 2023
Results "indicate that exa-cel can provide a one-time functional cure," says researcher
Jun 13, 2023
Findings could pave the way for considering common complication in stewardship programs
Jun 08, 2023
High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents
Jun 05, 2023
Continuing Medical Education
1.00 CME Credits